The Elgendy Lab specializes in drug discovery and medicinal chemistry, engaging in a comprehensive range of activities associated with various aspects of drug development. Their primary objective is to advance the field of medicinal chemistry by designing and synthesizing novel therapeutic agents.

Elgendy lab has predominantly focused on (a) the design and synthesis of modulators of nuclear hormone receptors (e.g., REV-ERB, ERR, LXR, FXR, and TLX) to validate these targets for the treatment of challenging diseases such as muscle injuries, Alzheimer’s disease, atherosclerosis, cancer, Fatty liver diseases, and pain.

The recent drug discovery efforts by Elgendy lab have been concentrated on three primary areas. Firstly, they are developing Central Nervous System (CNS)-active 5-HT3 receptor antagonists to treat neuropathic pain. Secondly, they are designing and developing new inhibitors of the mitochondrial protein complex to treat type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and neurodegenerative diseases. Lastly, they are working on discovering inhibitors of Cholesterol 25-hydroxylase (CH25H) to treat Alzheimer's disease.

Dr. Elgendy incorporates computational methods such as quantitative structure activity relationships, pharmacophore modeling, and virtual screening in his drug discovery pipeline to accelerate the process of drug discovery and optimization. 

• Lab Website